摘要
目的:探讨甘草酸二胺肠溶胶囊联合恩替卡韦治疗慢性乙型肝炎(CHB)肝纤维化的疗效。方法:选取93例CHB肝纤维化患者为研究对象,根据治疗方案不同分为联合组(n=46)和对照组(n=47)。对照组患者予以恩替卡韦治疗(0.5 mg/次,1次/d,连用12个月);联合组患者在对照组治疗基础上加服甘草酸二胺肠溶胶囊(150 mg/次,3次/d,连用3个月)。比较两组患者疗效及治疗后肝功能指标[门冬氨酸氨基转移酶(AST)、碱性磷酸酶(ALP)、丙氨酸氨基转移酶(ALT)]、HBV-DNA、肝脏硬度值(LSM)、AST/血小板比率指数(ARPI)、4因子结合的纤维化指数(FIB-4)、肝纤四项和血清炎症因子[白细胞介素6(IL-6)、超敏C反应蛋白(hs-CRP)]水平及不良反应发生情况。结果:联合组患者总有效率高于对照组(89.13%vs.74.47%,P<0.05)。治疗后,联合组患者ALT、ALP、AST、HBV-DNA和LSM、ARPI、FIB-4、IL-6、hs-CRP水平均低于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:对于CHB肝纤维化患者,甘草酸二胺肠溶胶囊联合恩替卡韦治疗能够更有效地缓解炎症,改善肝纤维化,延缓病情进展,且安全性好,值得临床推广。
Objective:To investigate the efficacy of diammonium glycyrrhizinate enteric-coated capsules combined with entecavir in the treatment of chronic hepatitis B(CHB)liver fibrosis.Methods:A total of 93 patients with CHB liver fibrosis were divided into control group(n=46)and combined group(n=47)according to different methods.The control group was treated with entecavir(0.5 mg/time,1 time/d,for 12 months),and the combined group was treated with diammonium glycyrrhizinate enteric-coated capsules(150 mg/time,3 times/d,for 3 months)on the basis of the control group.The curative effect,liver function indexes[aspartate aminotransferase(AST),alkaline phosphatase(ALP),alanine aminotransferase(ALT)],HBV-DNA,liver stiffness value(LSM),AST/platelet ratio index(ARPI),4 factor binding fibrosis index(FIB-4),liver fibrosis four items,serum inflammatory factors[interleukin-6(IL-6),high-sensitivity C-reactive protein(hs-CRP)]and the occurrence of adverse reactions were compared between the two groups before and after treatment.Results:The total effective rate of the combined group was 89.13%,which was higher than 74.47%of the control group(P<0.05).After treatment,the levels of ALT,ALP,AST,HBV-DNA,LSM,ARPI,FIB-4,IL-6,and hs-CRP in the combined group were lower than those in the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups of(P>0.05).Conclusion:For patients with CHB liver fibrosis,diammonium glycyrrhizinate enteric-coated capsules combined with entecavir can more effectively alleviate inflammation,improve liver fibrosis,delay the progress of the disease,and have good safety,which is worthy of clinical promotion.
作者
刘翔
李君
许芳
张婷
LIU Xiang;LI Jun;XU Fang;ZHANG Ting(Department of Pharmaceutical Division,Ma'anshan People's Hospital,Ma'anshan 243000,Anhui,China;Department of Infectious Diseasesc,Ma'anshan People's Hospital,Ma'anshan 243000,Anhui,China)
出处
《川北医学院学报》
CAS
2023年第7期889-892,共4页
Journal of North Sichuan Medical College
基金
国家自然科学基金项目(81802347)。
关键词
慢性乙型肝炎
肝纤维化
恩替卡韦
甘草酸二胺肠溶胶囊
炎症反应
Chronic hepatitis B
Liver fibrosis
Entecavir
Diammonium glycyrrhizinate enteric-coated capsules
Inflammatory response
